Out-licensing

A series of dimethane sulfonate compounds based on NSC 281612 that are suitable for the treatment of renal cancer.

Currently only a few small molecule inhibitors are effective in patients with renal cell carcinoma.  Approximately 30,000 patients per year are diagnosed with this disease but many of them are untreatable because of intrinsic drug resistance, and efficient drug transport and detoxification mechanisms.  This invention described and claimed in the patent application describes a series of dimethane sulfonate compounds based on NSC 281612 that are suitable for the treatment of renal cancer.  Compositions comprising a pharmaceutically-acceptable carrier and a compound, or a salt suitable for use in the treatment or prevention of renal cancer are also described.  The anti-tumor activity of NSC 281612 has been established in vivo against human renal tumor xenografts in mice.  Suitable dosing and administration schedules for treatment of renal tumors have also been determined in this study.

 

Applications:

For treatment or prevention of renal cancer.

 

Development Status:

The technology is currently in the pre-clinical stage of development.  Phase I clinical trials will begin this fall.

U.S. Patent Application No. 12/083,583 filed 14 Apr 2008, claiming priority to 14 Oct 2005 (HHS Reference No. E-249-2005/0-US-04)

 

Inventors:

Susan D. Mertins, Susan E. Bates, David G. Covell, Geoffrey W. Patton, Melinda G. Hollingshead, B. Rao Vishnuvajjala (NCI)

Licensees Sought:

Available for exclusive or non-exclusive licensing.

 

Collaborative Research Opportunity:

The National Cancer Institute, Screening Technologies Branch, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize biomarker assays for clinical utility (potential molecular targets have been identified).  Please contact John D. Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information.